Search for: "Anda Pharmaceuticals, Inc"
Results 81 - 100
of 605
Sort by Relevance
|
Sort by Date
18 Mar 2019, 10:57 am
Allergan USA, Inc. v. [read post]
11 Mar 2019, 7:08 pm
The asymmetry of this burden is especially salient in domains like pharmaceutical drugs and biosimilars, where the incentive to test the validity of patents has important social consequences, and the complexities of those decades-long disputes create fact patterns that can be difficult to unpack. [read post]
31 Jan 2019, 1:00 am
In 2011, Teva Pharmaceuticals USA, Inc. [read post]
7 Aug 2018, 8:20 am
ANI Pharmaceuticals, Inc., 2018 WL 3677923, No. 17-4910 (D. [read post]
18 Jul 2018, 11:23 am
Teva Pharmaceuticals USA, Inc., a case with broad implications for the pharmaceutical industry. [read post]
17 Jul 2018, 9:28 am
” Par Pharmaceutical, Inc. v. [read post]
5 Jul 2018, 1:37 pm
Rockville-based biopharmaceutical company CASI Pharmaceuticals Inc. has been added to the Russell 2000, 3000 and Microcap Indexes, effective after U.S. market closed June 22. [read post]
14 Apr 2018, 11:46 am
Delaware was affirmed:West-Ward Pharmaceuticals International Limitedand West-Ward Pharmaceuticals Corp. [read post]
29 Jan 2018, 12:51 pm
Rockville-based CASI Pharmaceuticals Inc., a biopharmaceutical company dedicated to bringing quality pharmaceutical products to the Chinese and U.S. markets, announced Monday it has acquired a portfolio of 25 U.S. [read post]
22 Dec 2017, 10:00 am
Sleet in Amgen Inc. v. [read post]
20 Sep 2017, 9:18 am
Mylan Pharmaceuticals Inc., where the Supreme Court held that “for purposes of determining personal jurisdiction in a Hatch-Waxman case, the Court must consider all future acts the ANDA filer non-speculatively intends to commit upon receiving final FDA approval for its ANDA product” to reach its conclusion that for purposes of determining venue “in the context of Hatch-Waxman litigation, the ‘acts of infringement’ an ANDA… [read post]
13 Sep 2017, 7:44 am
Mylan Pharmaceuticals, Inc., 1-17-cv-00379 (DED September 11, 2017, Order) (Stark, USDJ) [read post]
18 Jul 2017, 9:58 pm
Noonan -- In multiple ANDA litigations against multiple defendants, Millennium Pharmaceuticals, Inc. had several of its asserted claims held invalid for obviousness at the district court. [read post]
8 May 2017, 8:27 pm
Breckenridge Pharmaceutical, Inc., illustrates the risks a litigant can take when agreeing to stipulation in an effort at least to reduce litigation costs and issues presented at trial. [read post]
6 May 2017, 10:11 am
(“Braintree”) appealsfrom the Southern District of New York’s summary judgmentthat Breckenridge Pharmaceutical, Inc. [read post]
4 May 2017, 8:26 am
(“Helsinn”) brought suit against Teva Pharmaceuticals USA, Inc. and Teva Pharmaceutical Industries, Ltd. [read post]
4 May 2017, 8:26 am
(“Helsinn”) brought suit against Teva Pharmaceuticals USA, Inc. and Teva Pharmaceutical Industries, Ltd. [read post]
1 May 2017, 10:58 am
:Helsinn brought suit against Teva PharmaceuticalsUSA, Inc. and Teva Pharmaceutical Industries, Ltd. [read post]
26 Apr 2017, 7:24 am
Luitpold Pharmaceuticals, Inc. et al, 2-16-cv-02290 (NJD April 24, 2017, Order) (Walls, USDJ) [read post]
18 Apr 2017, 6:52 am
See Ariad Pharms., Inc. v. [read post]
